Cytokine modulators in the treatment of sarcoidosis

@article{Bargagli2011CytokineMI,
  title={Cytokine modulators in the treatment of sarcoidosis},
  author={Elena Bargagli and Carmela Olivieri and Paola Rottoli},
  journal={Rheumatology International},
  year={2011},
  volume={31},
  pages={1539-1544}
}
Sarcoidosis is a granulomatous lung disease in which several cytokines play a pivotal pathogenetic role. Steroid-resistant disease can be treated with immunosuppressive drugs, antimalarial therapies and recently with anti-TNFα agents. The use of biological agents for the treatment of sarcoidosis springs from research into the pathogenesis of the disease and also from the experience of rheumatologists with other chronic inflammatory diseases. Rituximab, golimumab and ustekinumab are cytokine… Expand
Anti-tumor necrosis factor-α agents in noninfectious uveitis.
TLDR
This review gives an update on the management of uveitis with TNF-α inhibitors, highlighting important issues, including initiation time, type of molecule, duration of therapy but also major adverse events. Expand
Targeting B Cells in Other Systemic Autoimmune Diseases
TLDR
There is anecdotal indication of successful use of rituximab in several conditions such as steroid-resistant and dependent sarcoidosis, Behcet disease with retinal vasculitis, chronic hepatitis C virus-associated polyarteritis nodosa, highly active refractory Takayasu arteritis, and Henoch–Schonlein purpura nephritis. Expand
C Sarcoidosis
Current Opinion in Ophthalmology 2011, 22:502–507 Purpose of review Sarcoidosis is a multisystem disorder that can include ocular lesions. Although the precise etiology of the disease is as yet notExpand
Successful Treatment of Ocular Sarcoidosis with Rituximab
TLDR
A 50-year-old woman who had been facing recurrent severe uveitis involving both the eyes for 3 years, with poor and transitory responses to topical treatments and oral steroid therapy, was referred to the Center for relapsing Uveitis. Expand
Sarcoidosis and the Th 1 chemokine MIG
Sarcoidosis is a systemic inflammatory disease, affecting any organ, and that can be discovered by accident in approximately 5% of cases. The most common symptoms are fatigue, weight loss, lack ofExpand
Extrapyramidal signs in neurosarcoidosis versus multiple sclerosis: Is TNF alpha the link?
TLDR
It is concluded that the specificity of extrapyramidal to NS raises the intriguing question of whether specific inflammatory pathways involving TNF-α play a role in the pathogenesis of PD and therefore may be a therapeutic target. Expand
Clinical phenotyping in sarcoidosis management
TLDR
In the heterogeneous context of this disease, N/L ratio proved to be a useful and simple routine laboratory biomarker related to disease activity and need for treatment. Expand
Sarcoidosis and Thyroid Autoimmunity
TLDR
Thyroid function, T POAb measurement, and ultrasonography should be done to assess the clinical profile in female S patients, and the ones at high risk (female individuals, with TPOAb positivity, and hypoechoic and small thyroid) should have periodically thyroid function evaluations and suitable treatments. Expand
Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis
TLDR
A comparative study of 12 Korean patients with paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman’s tumor found evidence of thymic differentiation and solid cell nest origin. Expand
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications.
TLDR
The present review focuses on the recent developments in the area of CSF-1R/c-FMS inhibitors with emphasis on crystal structure, mechanism of action and various therapeutic implications in which c-F MS plays a pivotal role. Expand
...
1
2
...

References

SHOWING 1-10 OF 104 REFERENCES
Treatment of therapy-resistant sarcoidosis with adalimumab
TLDR
Successful treatment using adalimumab, a human recombinant immunoglobulin (Ig) G1 anti-TNF monoclonal antibody is described, which indicates this cytokine plays a crucial role in granulomatous inflammation, e.g., in mycobacterial diseases. Expand
Targeting the TNF-α pathway in sarcoidosis
  • S. Antoniu
  • Medicine
  • Expert opinion on therapeutic targets
  • 2010
TLDR
In some subsets of sarcoidosis with more rapid progession and/or therapeutic refractoriness TNF-α plays a more prominent role in disease pathogenesis, and its blockade might represent an appropriate therapeutic approach. Expand
Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
TLDR
A stepwise approach is proposed to increase the likelihood of disease improvement for patients who experience an inadequate response to an anti-TNF agent as well as the relative benefits and side effects of the three anti- TNF biological agents for treating sarcoidosis. Expand
Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
TLDR
Sarcoidosis therapies with activity against tumor necrosis factor and specific anti-tumor necrosisFactor therapies have been used with variable success, and the long-term safety and efficacy of such therapies are yet to be determined in well-designed clinical trials with long- term follow-up. Expand
Infliximab for refractory sarcoidosis.
  • R. Baughman, E. Lower
  • Medicine
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
  • 2001
TLDR
Infliximab was associated with significant improvement in chronic sarcoidosis, and the index lesion was lupus pernio, which significantly improved with infliximab. Expand
Etanercept ameliorates sarcoidosis arthritis and skin disease.
TLDR
It is suggested that chronic, resistant sarcoidosis requires combination immunosuppressive therapy and the possible mechanisms of action of anti-TNF agents in granulomatous diseases are discussed. Expand
Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
We report on a 72 year-old woman with long-standing rheumatoid arthritis diagnosed as granulomatosis due to pulmonary sarcoidosis after 49 months of treatment with etanercept. A clinical andExpand
Refractory Chronic Cutaneous Sarcoidosis Responsive to Dose Escalation of TNF-Alpha Antagonists
TLDR
This case report reports the first patient with chronic cutaneous sarcoidosis who responded to dose escalation of anti-TNF-α agents that have been ineffective at the standard dosage, illustrating that the optimal dosing regimen has still to be defined for this indication before considering difficult-to-treat patients as nonresponders. Expand
Sarcoidosis: immunopathogenetic concepts and their clinical application.
TLDR
Using these approaches methotrexate, pentoxifylline and thalidomide have been identified as drugs which effectively suppress sarcoid inflammation and the serum level of soluble interleukin-2 receptors has been delineated to be a serum marker of sarcoids inflammation. Expand
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
TLDR
Thalidomide, particularly because of its inhibition of the macrophage function, may be a useful alternative therapy in steroid-resistant cases and the correlation between the angiotensin-converting enzyme level and the clinical improvement observed in patients suggests a direct parallel between angiotENSin- Converting enzyme and the activity of the granulomatous process. Expand
...
1
2
3
4
5
...